A new partnership between C2N Diagnostics and BeauBrain Healthcare will bring a breakthrough blood test for Alzheimer’s disease to South Korea, expanding access to earlier and more accurate detection of the condition.

 

Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test, an innovative diagnostic designed for patients aged 50 and older who show signs of mild cognitive impairment or dementia. 

 

The test helps physicians detect amyloid plaques in the brain — a key pathological hallmark of Alzheimer’s disease — and supports medical management and treatment decisions.

 

Interest in blood-based diagnostics for Alzheimer’s is already strong in South Korea. In a recent webinar survey, 72% of South Korean physicians said they would adopt such tests once available. The interest extended beyond neurologists and psychiatrists to include doctors in internal medicine and family medicine.

 

Recent findings from the Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD) highlight the test’s scientific promise. 

 

Researchers reported that C2N’s %p‑tau217 biomarker, a key component of the PrecivityAD2 test, is less affected by biological confounding factors such as body weight, kidney function and anemia than other p-tau217 immunoassays. The result is a more stable and reproducible diagnosis of amyloid pathology in patients with complex medical conditions.

 

C2N President and CEO Joel Braunstein welcomed the partnership, saying: “We endorse BeauBrain’s vision for ‘a world where all people can be free from the obscure fear of dementia’ and are proud they have selected C2N’s PrecivityAD2 blood test for this partnership. We recognize they have many options to choose from and their decision further affirms our role as a global leader in diagnostic testing for Alzheimer’s disease.”

 

BeauBrain co-CEO Jae Hak Kim emphasized the importance of early detection. “Early diagnosis is the entry point of successful and effective prevention when it comes to Alzheimer's disease."

 

“Without an early diagnosis, prevention for further progression cannot happen. I co-founded BeauBrain Healthcare to help deliver innovative solutions in a wide array of clinical settings and am honored to partner with C2N Diagnostics, given the rigorous scientific validation supporting the PrecivityAD2 blood test."